10.1016/j.jalz.2011.03.005
10.1016/j.jalz.2011.03.008
10.1016/j.jalz.2011.03.003
10.1016/j.jalz.2011.03.004
10.1212/WNL.0b013e3181d3e3e9
10.1212/WNL.0b013e3181f39adc
10.1212/WNL.0000000000000650
10.1001/jamaneurol.2014.3314
10.1016/S1474-4422(13)70044-9
10.1126/scitranslmed.3007901
10.1016/j.jalz.2016.02.002
10.1212/WNL.0000000000002923
10.1001/archneurol.2011.150
10.1016/S1474-4422(12)70142-4
10.1016/j.jalz.2015.05.018
Ikonomovic M Abrahamson E Kofler J Paljug W Debnath ML Price J et al. Neuropathology and biochemical correlations of [F‐18]AV‐1451 and [C‐11]PiB PET imaging in a subject with Alzheimer's disease. In: Johnson KA Jagust WJ Klunk WE Mathis CA eds. 11th Human Amyloid Imaging. Miami Florida: 2017. p. 157. Available at:www.worldeventsforum.com/hai.
10.1016/j.nicl.2016.11.008
10.1016/j.tips.2015.03.002
10.1016/S1474-4422(14)70252-2
10.1007/s00259-013-2681-7
10.1523/JNEUROSCI.4409-12.2013
10.1001/jamaneurol.2014.2031
10.1016/S1474-4422(13)70194-7
10.1212/WNL.0b013e3182a8418b
10.1212/WNL.0000000000001209
10.1016/S1474-4422(16)30125-9
10.1016/j.neurobiolaging.2016.03.025
10.1001/jamaneurol.2016.2237
10.1016/j.neurobiolaging.2015.08.029
10.1001/jamaneurol.2016.2642
Wirth M, 2013, Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people, JAMA Neurol, 70, 1512
10.1212/WNL.0b013e3182872830
Greene JA, 2007, Medicating Modern America: Prescription Drugs in History, 193
Karlawish J, 2010, Desktop medicine, JAMA, 304, 2061, 10.1001/jama.2010.1624
Sperling RA, 2011, Testing the right target and right drug at the right stage, Sci Transl Med, 3, 111 cm 33, 10.1126/scitranslmed.3002609
10.1038/nrneurol.2012.241
10.1007/s00401-011-0826-y
10.1212/WNL.0000000000001834
10.1016/j.neurobiolaging.2010.04.007
10.1212/01.wnl.0000261919.22630.ea
10.1186/s13195-016-0228-4
10.1016/j.jalz.2012.07.003
10.1016/j.jalz.2012.10.007
10.1212/WNL.0b013e318245d295
10.1016/S1474-4422(10)70223-4
10.1016/S1474-4422(11)70156-9
10.1212/01.wnl.0000219668.47116.e6
10.1016/0197-4580(91)90006-6
10.1212/01.wnl.0000228230.26044.a4
10.1001/archneur.65.11.1509
10.1016/j.jalz.2013.10.003
10.1016/j.jalz.2012.08.004
10.1016/S1474-4422(07)70178-3
10.1016/S1474-4422(14)70090-0
10.1001/archneur.64.3.noc60123
10.1016/S1474-4422(09)70139-5
10.1126/scitranslmed.aaf2362
10.1212/WNL.0000000000003050
10.1016/S0140-6736(01)05408-3
10.1523/JNEUROSCI.0150-15.2015
10.1001/jamaneurol.2013.182
10.1016/j.neurobiolaging.2009.07.002
10.1007/s00401-013-1157-y
10.1007/s00259-012-2237-2
10.1001/jamaneurol.2015.3098
10.1212/WNL.0000000000003812
10.1523/JNEUROSCI.0172-12.2012
10.1001/archneur.61.3.378
10.1097/WAD.0b013e318190a855
10.1212/WNL.0000000000002593
10.1007/s00401-011-0910-3
10.1016/j.jalz.2011.10.007
10.1212/WNL.0000000000002576
10.1001/archgenpsychiatry.2011.155
10.1016/j.jalz.2016.08.005
Klunk WE, 2012, Why we need two cutoffs for amyloid‐imaging: Early versus Alzheimer's‐like amyloid‐positivity. Alzheimer's Association International Conference, P453
Denoix P, 1946, Enquete permanente dans les centres anticancereux, Bull Inst Natl Hyg, 1, 12
Brierly JD, 2017, TNM Classification of Malignant Tumours, 8th Edition
10.1016/S1474-4422(03)00530-1
10.1212/WNL.0000000000001991
10.1212/WNL.0b013e3181bc010c
10.1016/j.jalz.2014.03.006
SJMakaretz MQuimby JCollins NMakris SMcGinnis ASchultz et al.Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry2017 Epub ahead of print
10.1186/s40478-016-0315-6
10.1007/s00401-017-1740-8
10.1016/j.neuron.2016.01.028
Lowe V, 2016, Human Amyloid Imaging, 114
10.1016/j.neurobiolaging.2017.01.024
10.2967/jnumed.117.194282
10.1001/jamaneurol.2016.5755
10.1523/JNEUROSCI.3769-16.2017
Pontecorvo MJ, 2017, Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition, Brain, 140, 748
10.2967/jnumed.115.171678
10.1016/S1474-4422(16)00070-3
10.1016/S0304-3940(00)01697-9
10.1212/01.wnl.0000242732.06714.0f
10.1001/jamaneurol.2013.6455
10.1016/j.neurobiolaging.2004.12.003
10.1001/archneurol.2008.596
CRJackJr. HJWiste SDWeigand TMTherneau DSKnopman VLowe et al.Age‐specific and sex‐specific prevalence of cerebral beta‐amyloidosis tauopathy and neurodegeneration in cognitively unimpaired individuals aged 50‐95 years: a cross‐sectional study. Lancet Neurol2017
10.1016/S1474-4422(12)70291-0
10.1016/S0306-4522(99)00476-5
10.1212/01.wnl.0000277459.83543.99
10.1212/WNL.0b013e3182704056
10.1212/WNL.0b013e3182918ca6
BDJames RSWilson PABoyle JQTrojanowski DABennett JASchneider.TDP‐43 stage mixed pathologies and clinical Alzheimer's‐type dementia. Brain2016
10.1016/j.biopsych.2012.08.015
10.1016/j.biopsych.2010.08.025
10.1007/s00401-016-1533-5
GRizzo MVeronese MTonietto BBodini BStankoff CWimberley et al.Generalization of endothelial modelling of TSPO PET imaging: considerations on tracer affinities. J Cereb Blood Flow Metab2017 271678X17742004
10.1136/bmjopen-2016-013187
10.1016/j.brainres.2010.09.073
MIKester CETeunissen DLCrimmins EMHerries JHLadenson PScheltens et al.Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol2015;1–7
10.1001/jamaneurol.2015.3037
10.1016/S1474-4422(07)70057-1
10.2967/jnumed.109.065870
ECMormino KVPapp DMRentz MCDonohue RAmariglio YTQuiroz et al.Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid‐beta. Alzheimers Dement2017
10.1212/WNL.0b013e3181cb3e25
10.1212/WNL.0b013e31821d753f
10.1212/WNL.0000000000000977
10.1111/j.1365-2796.2004.01388.x
American Psychiatric Association.Diagnostic and statistical manual of mental disorders : DSM‐5.5th ed.2013 Washington D.C.
10.1212/01.wnl.0000271090.28148.24
10.1001/archneurol.2011.157
Dunn B, 2018, Early Alzheimer's Disease: Developing Drugs for Treatment; Draft Guidance for Industry, 7060
10.1016/j.jalz.2015.05.017
Fischer CE, 2017, Determining the impact of psychosis on rates of false‐positive and false‐negative diagnosis in Alzheimer's disease, Alzheimers Dement, 3, 385, 10.1016/j.trci.2017.06.001
10.1016/j.neuroimage.2017.05.058
SSouthekal MDDevousSr. IKennedy MNavitsky MLu ADJoshi et al.Flortaucipir F 18 Quantitation using a Parametric Estimate of Reference Signal Intensity (PERSI). J Nucl Med2017 Epub ahead of print
10.1016/j.pneurobio.2014.02.004
10.1016/j.neuron.2013.01.002
10.1016/j.jalz.2014.07.003
10.1016/j.jalz.2014.05.1756
10.1016/j.jalz.2012.11.003
10.1016/j.cca.2016.05.014
10.1016/j.neuroimage.2011.07.098
10.1016/j.jalz.2017.06.2266
ANakamura NKaneko VLVillemagne TKato JDoecke VDoré et al.High performance plasma amyloid‐β biomarkers for Alzheimer's disease. Nature2018
10.1001/jamaneurol.2016.6117
10.1016/j.jalz.2016.06.001
10.1016/j.neurobiolaging.2017.01.017
10.1097/nen.0b013e31815c5efb
10.2174/156720512801322609
10.1016/S0197-4580(97)00056-0
10.1097/NEN.0b013e318232a379
10.1016/S1474-4422(14)70194-2
10.1371/journal.pone.0004144
10.1016/j.jalz.2015.12.006
10.1371/journal.pgen.1004606
Kaufman SK, 2016, Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability, In Vivo. Neuron, 92, 796, 10.1016/j.neuron.2016.09.055
10.1016/j.neuron.2014.04.047
10.1016/j.neuron.2013.12.003
10.1016/S1474-4422(09)70299-6
10.1186/s12860-017-0147-7
10.1001/jamaneurol.2017.0244
10.1016/j.neuron.2009.03.024
10.1016/j.jalz.2017.10.009
Andreasson U, 2016, Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders, Alzheimers Dement, 3, 98
10.1161/01.cir.0000437738.63853.7a